

**Freedom of Information Act Disclosure log  
- Reply Extract**

<b>File reference</b>	W21FOI077
<b>Key words</b>	Patients Treated by Dermatology and Gastroenterology Departments with Listed Dugs
<b>Date of release</b>	28/05/2021
<b>Attachments</b>	No

**You asked**

**1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:**

- **Adalimumab – Humira** = See notes below\*
- **Adalimumab Biosimilar** = See notes below\*
- **Apremilast** = See notes below\*
- **Brodalumab** = Five or fewer patients
- **Certolizumab** = See notes below\*
- **Dimethyl fumarate** = See notes below\*
- **Etanercept – Enbrel** = See notes below\*
- **Etanercept Biosimilar** = See notes below\*
- **Guselkumab** = See notes below\*
- **Infliximab – Remicade** = See notes below\*
- **Infliximab Biosimilar** = See notes below\*
- **Ixekizumab** = See notes below\*
- **Risankizumab** = Eight patients
- **Secukinumab** = See notes below\*
- **Tildrakizumab** = Five or fewer patients
- **Ustekinumab** = See notes below\*

**2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?**

- **Adalimumab – Humira**
- **Adalimumab Biosimilar**
- **Apremilast**
- **Brodalumab**
- **Certolizumab**
- **Dimethyl fumarate**
- **Etanercept – Enbrel**

- **Etanercept Biosimilar**
- **Guselkumab**
- **Infliximab – Remicade**
- **Infliximab Biosimilar**
- **Ixekizumab**
- **Risankizumab**
- **Secukinumab**
- **Tildrakizumab**
- **Ustekinumab**

The Trust does not record this information with a searchable filing system.

**3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

- **Adalimumab – Humira** = See notes below\*
- **Adalimumab Biosimilar** = See notes below\*
- **Golimumab** = See notes below\*
- **Infliximab – Remicade** = See notes below\*
- **Infliximab Biosimilar** = See notes below\*
- **Tofacitinib** = See notes below\*
- **Ustekinumab** = See notes below\*
- **Vedolizumab** = See notes below\*

\*The Trust provides the public with this information on a quarterly basis. The information is published here: <https://www.plymouthhospitals.nhs.uk/pharmacy>. Please refer to the legal notes below for more details.

### **Legal notes**

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Namely: Published information is exempt from further supply in accordance with section 21.-(1).- Information accessible by other means.

The Trust is also refusing to publish information intended for later publication. Please note the Trust only publishes quarterly periods to avoid the risk of patients being identified, to minimise the impact on clinical services and reduce the cost to the public purse.

The 2020/21 fourth quarter data will be available shortly. The publication date is currently undecided. As such requests outside this publishing regime are refused in compliance with section 22. - Information intended for later publication.



Some data sets are listed as five or fewer. This avoids a breach of the first two Data Protection Act principles and the general right to object to processing. This is in accordance with section 40.(2)(a) and (b) by virtue of the first and second condition. Exact numbers are refused because they constitute personal information and exempt from supply in accordance with section 40(2) - Personal information.

**Attachments included:** No